Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBT (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBT for 6 consecutive years, with -$54.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 27.74% to -$54.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$275.7 million through Dec 2025, up 18.36% year-over-year, with the annual reading at -$275.7 million for FY2025, 18.36% up from the prior year.
  • EBT for Q4 2025 was -$54.9 million at Relay Therapeutics, up from -$74.0 million in the prior quarter.
  • The five-year high for EBT was -$42.2 million in Q1 2021, with the low at -$193.4 million in Q2 2021.
  • Average EBT over 5 years is -$80.5 million, with a median of -$76.4 million recorded in 2022.
  • The sharpest move saw EBT plummeted 623.69% in 2021, then soared 60.29% in 2022.
  • Over 5 years, EBT stood at -$67.5 million in 2021, then dropped by 0.03% to -$67.5 million in 2022, then decreased by 23.74% to -$83.5 million in 2023, then increased by 8.97% to -$76.0 million in 2024, then grew by 27.74% to -$54.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$54.9 million, -$74.0 million, and -$69.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.